Research programme: bispecific antibodies - Astellas Pharma/Xencor
Alternative Names: Bispecific Antibody Program - Astellas Pharma/XencorLatest Information Update: 28 Nov 2024
At a glance
- Originator Astellas Pharma; Xencor
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T-lymphocyte subset stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Cancer in Japan (Parenteral)
- 28 Nov 2024 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 22 Oct 2020 Preclinical trials in Cancer in Japan (Parenteral), Prior to October 2020 ( Xencor pipeline, October 2020)